Sarepta Therapeutics, Inc. (SRPT) was raised to ‘Outperform’ from ‘Neutral’ and it was given $36 price target at Wedbush on Tuesday.
SRPT is up $3.44 at $19.49 on heavy volume. Midway through trading Tuesday, 15.57 million shares of Sarepta Therapeutics Inc. have exchanged hands as compared to its average daily volume of 9.92 million shares. The stock ranged in a price between $19.11-$21.88 after having opened the day at $21.19 as compared to the previous trading day’s close of $16.05.
In other news Sarepta Therapeutics today announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA).
Citigroup reported on Tuesday that they have lowered their rating for Biogen Inc. (BIIB). The firm has downgraded BIIB from ‘Buy’ to ‘Neutral’.
Biogen Inc. recently traded at $254.70, a loss of $35.14 over Monday’s closing price. The name has a current market capitalization of $55.79 billion.
Regulus Therapeutics Inc. (RGLS) rating of ‘Buy’ was reiterated today at Chardan Capital Markets with a price target increase of $20 from $15 (versus a $5.94 previous close).
RGLS shares declined 6.06% to $5.58 in mid-day trading.
Western Digital Corporation (WDC) had its rating hiked to ‘Buy’ from ‘Neutral’ by Mizuho today. The firm currently has a $53 price target on the stock.
WDC shares recently gained $1.73 to $49.75. The stock is down 47.73% year-over-year and has lost roughly 19.20% year-to-date. In the past 52 weeks, shares of Irvine California-based company have traded between a low of $34.99 and a high of $94.86.